Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents

Journal of Viral Hepatitis

Volumn 18, Issue 1, 2011, Pages 32-41

  Grebely, J ^a   Raffa, J D ^b   Lai, C ^c   Kerr, T ^c   Fischer, B ^d   Krajden, M ^e   Dore, G J ^a   Tyndall, M W ^c,e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WATERLOO   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

hepatitis C virus; HIV; illicit drug use; injection drug use; mortality

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CITY; DIGESTIVE SYSTEM FUNCTION DISORDER; ENDOCRINE DISEASE; FEMALE; GROUPS BY AGE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVER CANCER; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; NEOPLASM; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; VIRUS HEPATITIS;

ADULT; BRITISH COLUMBIA; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; SUBSTANCE-RELATED DISORDERS; SURVIVAL ANALYSIS; URBAN POPULATION;

EID: 78650279510     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01279.x     Document Type: Article

References (30)

1. Simonetti RG, Cottone M, Craxi A, et al. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma. Lancet 1989; 2 (8675): 1338. (Pubitemid 20005713)
2. Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2 (8670): 1006-1008. (Pubitemid 19257916)
3. Ponz E, Garcia-Pagan JC, Bruguera M, Bruix J, Rodes J,. Hepatic fibrin-ring granulomas in a patient with hepatitis A. Gastroenterology 1991; 100 (1): 268-270.
4. Seeff LB,. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl. 1): S35-S46.
5. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48 (2): 418-431.
6. Neal KR, Ramsay S, Thomson BJ, Irving WL,. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56 (8): 1098-1104.
7. Harris HE, Ramsay ME, Andrews N, Eldridge KP,. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002; 324 (7335): 450-453. (Pubitemid 34169458)
8. Harris HE, Ramsay ME, Andrews NJ,. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect 2006; 134 (3): 472-477.
9. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N,. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32 (3): 582-587.
10. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132 (2): 105-111. (Pubitemid 30044176)
11. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33 (2): 455-463.
12. Osella AR, Misciagna G, Guerra VM, et al. Hepatitis C virus (HCV) infection and liver-related mortality: a population-based cohort study in southern Italy. The Association for the Study of Liver Disease in Puglia. Int J Epidemiol 2000; 29 (5): 922-927.
13. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ,. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368 (9539): 938-945. (Pubitemid 44331386)
14. McDonald SA, Donaghy M, Goldberg DJ, et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2008; 18 (3): 271-283.
15. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284 (4): 450-456. (Pubitemid 30484478)
16. Copeland L, Budd J, Robertson JR, Elton RA,. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med 2004; 164 (11): 1214-1220. (Pubitemid 39030358)
17. Vlahov D, Wang CL, Galai N, et al. Mortality risk among new onset injection drug users. Addiction 2004; 99 (8): 946-954. (Pubitemid 39452806)
18. Ferreros I, Lumbreras B, Hurtado I, Perez-Hoyos S, Hernandez-Aguado I,. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction 2008; 103 (4): 651-659. (Pubitemid 351389277)
19. Bird SM, Hutchinson SJ, Goldberg DJ,. Drug-related deaths by region, sex, and age group per 100 injecting drug users in Scotland, 2000-01. Lancet 2003; 362 (9388): 941-944.
20. Vlahov D, Wang C, Ompad D, et al. Mortality risk among recent-onset injection drug users in five U.S. cities. Subst Use Misuse 2008; 43 (3-4): 413-428. (Pubitemid 351448738)
21. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT,. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001; 28 (4): 351-357. (Pubitemid 33101288)
22. Degenhardt L, Hall W, Warner-Smith M,. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006; 82 (Suppl. 3): iii56-iii63. (Pubitemid 43901613)
23. Smit C, Van Den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M,. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008; 47 (2): 221-225. (Pubitemid 351172190)
24. Lumbreras B, Jarrin I, Del Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006; 20 (1): 111-116. (Pubitemid 41818121)
25. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32 (3): 492-497. (Pubitemid 32173638)
26. Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41 (6): 864-872. (Pubitemid 41266755)
27. Muga R, Langohr K, Tor J, et al. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis 2007; 45 (3): 370-376. (Pubitemid 47101036)
28. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190 (6): 1046-1054. (Pubitemid 39186789)
29. BCVSA. Selected Vital Statistics and Health Status Indicators.Annual Report 2006. Victoria: British Columbia Vital Statistics Agency, 2006.
30. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16 (5): 352-358.